title: Recommendations for vaccination against pneumococcus in kidney patients in Spain.
abstract: Invasive pneumococcal disease (IPD) is a serious problem in some risk groups: patients with stage 4 and 5 chronic kidney disease, stage 3 CKD undergoing immunosuppressive treatment, nephrotic syndrome or diabetes. These individuals are more susceptible to infections and more prone to suffering more severe and worsening symptoms. Vaccination is one of the strategies for preventing IPD, although vaccination coverage in this group at present is lower than desired. Currently, there are two vaccinations for adults. The polysaccharide vaccine (PPSV23), used for decades in patients over the age of 2, includes most serotypes (23), but it does not generate immune memory, causing the immune tolerance phenomenon and it does not act on nasopharyngeal colonisation. The conjugate vaccine (VNC13) can be used from infancy until adulthood (advice in patients over 18 years old received approval from the European Medicines Agency in July 2013) and generates a more powerful immune response than PPSV23 against the majority of the 13 serotypes that it includes. The 16 scientific societies most directly associated with the groups at risk of IPD have discussed and drafted a series of vaccination recommendations based on scientific evidence related to pneumococcal vaccination in adults with underlying conditions and pathologies, which are the subject of the document &ldquo;
  
  
  METHODS
  Pneumococcal vaccination in adults with underlying pathology&rdquo;. This text sets out the vaccination recommendations for the chronic kidney disease population.
authors.forename: José
authors.initials: J
authors.lastname: Portolés-Pérez
authors.forename: María
authors.initials: M
authors.lastname: Marques-Vidas
authors.forename: Juan J
authors.initials: JJ
authors.lastname: Picazo
authors.forename: Fernando
authors.initials: F
authors.lastname: González-Romo
authors.forename: Amós
authors.initials: A
authors.lastname: García-Rojas
authors.forename: Emilio
authors.initials: E
authors.lastname: Pérez-Trallero
authors.forename: Pedro
authors.initials: P
authors.lastname: Gil-Gregorio
authors.forename: Rafael
authors.initials: R
authors.lastname: de la Cámara
authors.forename: M Luisa
authors.initials: ML
authors.lastname: Morató
authors.forename: Alejandro
authors.initials: A
authors.lastname: Rodríguez
authors.forename: José
authors.initials: J
authors.lastname: Barberán
authors.forename: Vicente
authors.initials: V
authors.lastname: Domínguez-Hernández
authors.forename: Manuel
authors.initials: M
authors.lastname: Linares-Rufo
authors.forename: Isabel
authors.initials: I
authors.lastname: Jimeno-Sanz
authors.forename: Francisco
authors.initials: F
authors.lastname: Sanz-Herrero
authors.forename: Javier
authors.initials: J
authors.lastname: Espinosa-Arranz
authors.forename: Valle
authors.initials: V
authors.lastname: García-Sánchez
authors.forename: María
authors.initials: M
authors.lastname: Galindo-Izquierdo
authors.forename: Alberto
authors.initials: A
authors.lastname: Martínez-Castelao
mesh_terms: D006801:Humans; D011008:Pneumococcal Infections / Q000150:complications / Q000453:epidemiology / Q000517:prevention & control*; D022242:Pneumococcal Vaccines; D017410:Practice Guidelines as Topic; D051436:Renal Insufficiency, Chronic / Q000150:complications; D012307:Risk Factors; D013030:Spain; D014611:Vaccination
chemical_list: D022242:Pneumococcal Vaccines